The Tempus artificial intelligence (AI)-driven algorithms platform leverages our molecular and clinical database, CAP/CLIA lab, and clinician network to develop tests that help inform the treatment of cancer patients.
Tempus HRD is a laboratory developed test to predict the probability of a patient’s cancer having a phenotype characterized by the inability to repair DNA breaks via the homologous recombination repair (HRR) pathway, known as homologous recombination deficiency (HRD). It is available as an additional test for patients who are tested with Tempus xT.
For ovarian and breast cancer where DNA based methods of HRD detection are common or under investigation, Tempus HRD provides a result based on DNA genome-wide loss of heterozygosity (GWLOH) or evidence of biallelic BRCA1 or BRCA2 loss. For patients with other cancers, Tempus HRD provides an HRD score based on whole transcriptome RNA expression.
HRD can be ordered as an add-on with any Tempus xT test, without additional tissue samples.
Gain additional insight into a patient’s tumor molecular phenotype on top of the genomic profiling results assessed by xT.
The Tempus Tumor Origin (TO) test uses tumor RNA expression results to predict the patient’s most likely cancer type(s) from 68 possible cancer types. The Tempus TO test was developed using a large internal database of clinical and annotated molecular tumor data.
The intended use of the TO test is for cancers of unknown primary and cases for which the available diagnostic information, such as imaging and immunohistochemistry results, do not provide a definitive diagnosis. When paired with xT, the TO results may provide insight into the patient’s diagnosis and tumor site of origin that may be used to inform patient care and clinical trial eligibility.
TO can be ordered as an add-on with the Tempus xT Solid Tumor + Normal test, without additional tissue samples.
The test characterizes 68 possible cancer types to provide precise information for guiding treatment decisions.
The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase (DPD), a key protein involved in 5-FU/Capecitabine metabolism.
The Tempus DPYD test is designed to help physicians to better identify patients who may be at risk for toxicity and serious adverse effects from 5-FU/Capecitabine. It is applicable in situations where 5-FU/Capecitabine treatments are considered, especially colorectal, breast, pancreatic, and other GI cancers.
DPYD can be ordered as an add-on with the Tempus xT Solid Tumor + Normal test, without additional tissue samples.
DPYD analysis covers five SNVs in DPYD genes, providing a more complete patient profile.